ATE462787T1 - Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington - Google Patents

Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington

Info

Publication number
ATE462787T1
ATE462787T1 AT07290751T AT07290751T ATE462787T1 AT E462787 T1 ATE462787 T1 AT E462787T1 AT 07290751 T AT07290751 T AT 07290751T AT 07290751 T AT07290751 T AT 07290751T AT E462787 T1 ATE462787 T1 AT E462787T1
Authority
AT
Austria
Prior art keywords
huntington
disease
treatment
application
type
Prior art date
Application number
AT07290751T
Other languages
German (de)
English (en)
Inventor
Valerie Perrin
Nicole Deglon
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of ATE462787T1 publication Critical patent/ATE462787T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT07290751T 2007-06-18 2007-06-18 Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington ATE462787T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290751A EP2014769B1 (en) 2007-06-18 2007-06-18 Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease

Publications (1)

Publication Number Publication Date
ATE462787T1 true ATE462787T1 (de) 2010-04-15

Family

ID=38476952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07290751T ATE462787T1 (de) 2007-06-18 2007-06-18 Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington

Country Status (7)

Country Link
US (1) US8217018B2 (https=)
EP (1) EP2014769B1 (https=)
JP (1) JP5401451B2 (https=)
AT (1) ATE462787T1 (https=)
CA (1) CA2690730C (https=)
DE (1) DE602007005629D1 (https=)
WO (1) WO2009007855A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726866A1 (en) * 2008-05-09 2009-11-12 The University Of British Columbia Methods and compositions for the treatment of huntington's disease
US8679750B2 (en) 2008-05-09 2014-03-25 The University Of British Columbia Methods and compositions for the treatment of Huntington'S disease
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
CA2789038A1 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
US8957040B2 (en) 2010-02-08 2015-02-17 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
WO2012004778A1 (en) * 2010-07-09 2012-01-12 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
CN104968783B (zh) 2012-10-15 2019-12-10 Ionis制药公司 用于调节c9orf72表达的组合物
EP2906697A4 (en) 2012-10-15 2016-06-22 Ionis Pharmaceuticals Inc METHOD FOR MONITORING THE C9ORF72 EXPRESSION
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2015070212A1 (en) * 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2015171932A1 (en) * 2014-05-08 2015-11-12 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
RS60230B1 (sr) 2015-04-16 2020-06-30 Ionis Pharmaceuticals Inc Kompozicije za moduliranje ekspresije c9orf72
IL320434A (en) 2015-07-22 2025-06-01 Wave Life Sciences Ltd Oligonucleotide preparations and methods
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
EP3452596A4 (en) 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS

Also Published As

Publication number Publication date
EP2014769A1 (en) 2009-01-14
WO2009007855A3 (en) 2009-04-02
CA2690730C (en) 2018-07-31
JP5401451B2 (ja) 2014-01-29
EP2014769B1 (en) 2010-03-31
US8217018B2 (en) 2012-07-10
CA2690730A1 (en) 2009-01-15
WO2009007855A2 (en) 2009-01-15
DE602007005629D1 (de) 2010-05-12
JP2010530239A (ja) 2010-09-09
US20100299768A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
ATE462787T1 (de) Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
WO2006084209A3 (en) Rnai expression constructs
PL2257155T3 (pl) Krioprezerwacja komórek i tkanek biologicznych
ATE521711T1 (de) In-vivo-screening-modelle zur behandlung der alzheimer-krankheit und anderer erkrankungen in zusammenhang mit dem qpct-gen
WO2012067970A3 (en) Transcriptional repression leading to parkinson's disease
EP2303292A4 (en) COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC
WO2010017562A3 (en) Induced pluripotent stem cells
EP2414548A4 (en) GENE EXPRESSION ANALYSIS IN SINGLE CELLS
EP2250497A4 (en) CELL PROCESSING AND / OR ENRICHMENT PROCESS
WO2008144021A3 (en) Ex vivo methods for validating substance testing with human organs and/or tissues
WO2013158309A3 (en) Non-disruptive gene targeting
IN2009DN07390A (https=)
EP2641911A3 (en) Compositions and methods for re-programming cells without genetic modification
BR112013000267A2 (pt) produção de cassete de dna linear funcionalizado e distribuição mediada por ponto quântico/nanopartícula em plantas
WO2007064846A3 (en) COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION
FR2917975B1 (fr) Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
ATE519777T1 (de) Magnetosomen-genexpression in eukaryotischen zellen
WO2009047809A3 (en) Sequence variants for inferring human pigmentation patterns
EP1874922A4 (en) METHOD USING STROMA CELLS FROM UMBILICAL CORD BLOOD TO DEVELOP AND GRAFT NUCLEAR CELLS DERIVED FROM UMBILICAL CORD BLOOD
EP2285968A4 (en) CHIMERIC COMPOSITIONS AND METHOD FOR REGULATING GENE EXPRESSION IN PLANTS
CR8547A (es) Composiciones y metodos relacionados con el cultivo de celulas madre neurales con celulas estromales de medula osea
Čunderlíková Clinical significance of immunohistochemically detected extracellular matrix proteins and their spatial distribution in primary cancer
EP2415868A4 (en) METHOD AND KIT FOR EVALUATING OBESITY DEVELOPMENT PREDISPOSITION, ANTI-OBESITY AGENT AND SCREENING METHOD, NON-HUMAN ANIMAL, ADIPOSE TISSUE, ADIPOCYTE, PROCESS FOR PRODUCTION OF TRANSGENIC MOUSE, ANTIGEN, AND 'ANTIBODY
EP1963514A4 (en) PROCESS FOR THE PHOTOTRANSFICATION OF NUCLEIC ACID IN LIVING CELLS
EP2430178A4 (en) METHOD AND KITS FOR MEASURING TOXICITY AND OXIDATIVE STRESS IN LIVING CELLS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties